Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥141.00 - ¥368.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)588.79K
Market Cap
¥9.28B
Enterprise Value¥13.10B
Total Cash (Recent Filing)¥5.38B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Dec 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.69
Shares Outstanding62,681,200
10 Day Avg. Volume343,580
30 Day Avg. Volume588,790
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.26
Price to Sales (P/S)0.00
P/FCF Ratio-11.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageEssentially no debt limits leverage and interest-burden risk, preserving financial flexibility if the company needs to adjust spending or pursue funding. This balance-sheet characteristic provides a meaningful cushion even though operating performance and capital levels remain weak.
Prior Cash-generation CapabilityPositive operating and free cash flow in 2023 shows that the business has previously generated cash internally rather than relying exclusively on external funding. Although this strength has not persisted, it provides evidence of historical cash-generation capability that could matter if operations recover.
Historical Earnings CapacityStrong revenue and positive earnings in 2023 demonstrate that the company has previously reached a profitable operating state. The result was followed by a sharp deterioration, so it is not evidence of current durability, but it indicates that earnings capacity has existed rather than being entirely unproven.
Bears Say
Revenue Has Fallen To ZeroZero reported revenue across three consecutive years indicates that commercial activity has not translated into recurring top-line performance. This undermines revenue visibility, weakens operating leverage, and makes a durable path toward self-funded growth difficult over the next several quarters.
Persistent Operating LossesLarge and expanding operating and net losses show that the company is not currently covering its cost base through revenue. Continued losses can erode capital, reduce strategic flexibility, and make any future recovery more dependent on successful execution and additional financing.
Sustained Cash Burn And Capital ErosionSustained operating and free-cash-flow deficits directly increase funding and runway risk, while declining equity and assets indicate that losses are consuming the balance-sheet base. Even with minimal debt, this combination can constrain investment and raise reliance on future capital.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥141.00 and its highest was ¥368.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥9.28B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Dec 16, 2026 which is in 53 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Sep 09, 2026. The company reported -¥7.12 earnings per share for the quarter.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥7.12 in its last earnings report. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―